hims and hers tirzepatide | Women's Healthcare, Online Hims and Hers Weight Loss

OASIS 4 trial: In adults with obesity or overweight with at least one weight-related comorbidity, along with diet and exercise, Wegovy pill achieved significant weight loss 1 Analysis of all patients regardless of if they stayed on treatment Co-primary end point: Percent change in body weight 1 ** Co-primary end point: Reduction in body weight of 5% 1 Proportion of patients achieving 5% weight loss at 64 weeks Confirmatory secondary end points (week 64) 1 10% weight loss: 59.8% Wegovy pill vs 14.4% placebo 15% weight loss: 47% Wegovy pill vs 5.5% placebo 20% weight loss: 27.9% Wegovy pill vs 3.1% placebo If all patients stayed on treatment ~ 17% (16.6%) mean weight loss with Wegovy pill vs 2.7% with placebo at 64 weeks, in an idealized scenario estimating efficacy if all patients remained on treatment and used no other weight-loss therapies 3 Mean baseline body weight 1 : Wegovy =234.6 lb

It also involves several other aspects that make the procedure much more beneficial and safer

Consider Semaglutide (Ozempic) or Liraglutide (Saxenda) - like Tirzepatide's weight-loss buddies

Topical GHK-CU dosing Topical application suits facial rejuvenation, localized skin concerns, and maintenance protocols